Skip to main content

Table 2 Split of drug costs into pre- and post-progression periods, per patient

From: Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma

 

Pre-progression index drugs

Pre-progression concomitant drugs

Post-progression index drugs

Post-progression subsequent melanoma drugs

Post-progression concomitant drugs

Pre-progression drug costs

Post-progression drug costs

Total drug costs

UK analysis

 NIVO + IPI (n = 177)

£135,584

£4994

£17,021

£54,096

£3262

£140,578

£74,379

£214,957

 IPI (n = 167)

£66,115

£1081

£4413

£145,037

£4032

£67,196

£153,482

£220,678

 NIVO (n = 170)

£109,653

£1621

£25,936

£99,448

£2843

£111,274

£128,266

£239,540

 Difference (NIVO + IPI vs. IPI

105%

362%

286%

− 63%

− 19%

109%

− 52%

− 3%

 Difference (NIVO + IPI vs. NIVO)

24%

208%

− 34%

− 46%

15%

26%

− 42%

− 10%

Germany analysis

 NIVO + IPI (n = 177)

€133,743

€10,621

€17,106

€52,940

€8897

€144,364

€78,943

€223,307

 IPI (n = 167)

€63,773

€2646

€4250

€152,395

€9865

€66,419

€166,510

€232,929

 NIVO (n = 170)

€110,977

€5901

€26,235

€97,889

€7749

€116,878

€131,873

€248,751

 Difference (NIVO + IPI vs. IPI

110%

301%

302%

− 65%

− 10%

117%

− 53%

− 4%

 Difference (NIVO + IPI vs. NIVO)

21%

80%

− 35%

− 46%

15%

24%

− 40%

− 10%

  1. NIVO + IPI nivolumab + ipilimumab cohort, NIVO nivolumab monotherapy cohort, IPI ipilimumab monotherapy cohort